Lilly's diabetes shot achieves record weight loss

Eli Lilly & Co.'s highly anticipated experimental medicine has achieved unprecedented weight loss results in diabetic patients, surpassing current market offerings. This significant outcome highlights the drug's potential in the rapidly growing market for next-generation therapies. The study underscores Lilly's competitive edge in developing innovative treatments for diabetes and obesity.